Impact of para-aortic lymphadenectomy on clinically FIGO stage IIIC1 high- grade endometrial cancer: a retrospective cohort study from two tertiary centers Running title: Lymphadenectomy in high-grade endometrial cancer

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

The therapeutic effect of para-aortic lymphadenectomy in patients with clinically pelvic node-positive but para-aortic node-negative endometrial cancer remains controversial. In this study, we investigated whether combined pelvic and para-aortic lymphadenectomy has a survival benefit compared with pelvic lymphadenectomy alone in these patients. We retrospectively reviewed patients with clinically FIGO stage IIIC1 high-grade endometrial cancer at two tertiary centers. Patients were stratified according to type of lymphadenectomy and subgroup analyses were performed. Kaplan–Meier analysis and a Cox proportional-hazards model were used to evaluate survival outcomes. A total of 56 patients were identified. Of these patients, 18 underwent pelvic lymphadenectomy alone, and 38 underwent combined pelvic and para-aortic lymphadenectomy. After staging surgery, 34 (60.7%) patients had pathologically confirmed lymph node metastases. Within a median follow-up of 57.5 months, there were no significant differences in recurrence-free survival (RFS) and overall survival (OS) between the two groups. In subgroup analyses, the node- and lymphovascular space invasion (LVSI)-positive patients characterized by grade 3 endometrioid histologic type (p = 0.010) or negative peritoneal washing cytology (p = 0.035) had an RFS benefit from combined pelvic and para-aortic lymphadenectomy.

Article activity feed